See ratings and reviews when you sign up for an account.

Vyvanse and Glucose Intolerance in Children With ADHD and Obesity

This study is currently Recruiting

June 2011 By Duke University

First Recieved on November 19, 2009

Last Updated on June 12, 2011

Sponsor: Duke University
Collaborators: Shire Pharmaceutical Development
Information provided by: Duke University
Identifier: NCT01017263


The purpose of this study to assess the effects of chronic administration of Vyvanse (lis-dexamphetamine) on glucose metabolism in a sample of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) who also have glucose intolerance and are obese.

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Ages Eligible for Study:8 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:Accepts Healthy Volunteers

Inclusion Criteria: - male or female, ages between 8 and 17 - Body Mass Index > 30 - fasting blood sugar between 90-100 mg/dl - 2 hour post prandial >140 <180 mg/dl - meets criteria for a diagnosis of ADHD, any subtype Exclusion Criteria: - known cardiovascular disease or diabetes - structural cardiac abnormalities, abnormal ECGs, family history of sudden death - positive urine drug screen - fasting blood sugar level > 126 mg/dl - HbA1c > 6.5 % - Weight > 300 lbs


  • Investigator: Scott H Kollins, PhD - Principal Investigator - Duke University


  • Duke Child and Family Study Center

    Durham, North Carolina 27705 United States

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.